Lytix Biopharma AS Ratios and Metrics

Market cap in millions NOK. Fiscal year is January - December.

Millions NOK. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Mar '26 Mar 9, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Market Capitalization	731	674	401	195	311	533	Upgrade
Market Cap Growth	107.41%	68.03%	106.12%	-37.37%	-41.63%	-	Upgrade
Enterprise Value	660	587	361	116	139	323	Upgrade
Last Close Price	9.50	9.83	5.85	4.84	7.72	13.69	Upgrade
PS Ratio	-	-	36.05	48.79	28.19	27.59	Upgrade
PB Ratio	11.83	10.92	3.72	3.80	2.30	2.81	Upgrade
P/TBV Ratio	11.83	10.92	3.72	3.80	2.30	2.81	Upgrade
EV/Sales Ratio	-	-	32.39	29.06	12.63	16.76	Upgrade
Debt / Equity Ratio	0.04	0.04	0.02	0.01	0.01	0.01	Upgrade
Net Debt / Equity Ratio	-1.14	-1.14	-1.19	-0.97	-1.06	-1.03	Upgrade
Net Debt / EBITDA Ratio	1.10	1.10	1.34	0.52	2.19	4.11	Upgrade
Net Debt / FCF Ratio	1.17	1.17	1.82	0.52	2.73	4.37	Upgrade
Asset Turnover	-	-	0.11	0.04	0.06	0.16	Upgrade
Quick Ratio	4.28	4.28	3.90	5.01	8.51	14.29	Upgrade
Current Ratio	4.28	4.28	3.91	5.06	8.55	14.33	Upgrade
Return on Equity (ROE)	-70.71%	-70.71%	-118.41%	-94.33%	-34.54%	-45.90%	Upgrade
Return on Assets (ROA)	-35.09%	-35.09%	-56.97%	-55.72%	-22.90%	-25.23%	Upgrade
Return on Capital Employed (ROCE)	-101.70%	-101.70%	-87.40%	-188.40%	-48.50%	-25.10%	Upgrade
Earnings Yield	-8.21%	-8.89%	-23.48%	-45.14%	-18.03%	-9.03%	Upgrade
FCF Yield	-	-8.87%	-17.53%	-49.31%	-16.98%	-8.37%	Upgrade
Buyback Yield / Dilution	-26.05%	-26.05%	-35.05%	-1.01%	-19.50%	-26.57%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.